Curative Biotechnology Inc CUBT

Healthcare Biotechnology

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. It is primarily focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its development pipeline is focused on three therapeutic areas: infectious diseases, oncology, and degenerative eye disease. Under these therapeutic areas, it has targeted three programs: Rabies, Glioblastoma, and Degenerative Eye Diseases. IMT504 is a synthetic immunotherapy to treat late-stage rabies as a stand-alone therapy.